Cantor Fitzgerald Starts Rosetta Genomics (ROSG) at Hold

Cantor Fitzgerald initiated coverage on Rosetta Genomics (NASDAQ: ROSG) with a Hold rating and a price target of $4.00.

Analyst Sung Ji Nam said, "Rosetta Genomics is a pioneer in leveraging microRNAs to develop diagnostic products. microRNAs are small non-coding RNAs that play an important role in protein production and have been implicated in various diseases, including cancer, cardiovascular and neurological diseases. The company currently offers four cancer diagnostic tests through its CLIA lab, including the Cancer Origin Test (COT) that represents the majority of its revenue."

"While Rosetta’s products have been commercially available for a few years, we have yet to see meaningful revenue ramp, and we think the biggest hurdle is the lack of robust clinical evidence for improved patient outcomes. We would like to see additional clinical data for Rosetta's two substantial product opportunities, which are expected to be available over the next twelve months, before turning more constructive on ROSG," added the analyst.

For an analyst ratings summary and ratings history on Rosetta Genomics click here. For more ratings news on Rosetta Genomics click here.

Shares of Rosetta Genomics closed at $2.91 yesterday.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• UBS Reiterates Buy Rating on HF Sinclair (DINO)